Title: Clinical MR Spectroscopy
1Clinical MR Spectroscopy
- Lawrence N. Tanenbaum, M.D. FACR
- New Jersey Neuroscience Institute
- Seton Hall School of Graduate Medical Education
- drt_at_drtmasters.com www.drtmasters.com
- JFK Medical Center Edison Imaging
- Edison, New Jersey
1.5 T
3.0 T
2What is MR Spectroscopy?
- EM energy impinges on a sample which then absorbs
or emits energy that can be measured. - Energy distribution and intensity provides
information about the samples physical and
chemical properties. - Functional (chemical) MRS information complements
structural MRI information.
3Functional MRtechniques
- Spectroscopy
- single voxel
- MRSI
- Diffusion
- DWI
- anisotropy
- Perfusion
- CBV, MTT, CBF
- Activation
- BOLD
4MRS techniquesmetabolites
- Proton (H)
- 1.5-3T scanner with routine hardware
- clinical software widely available
- Phosphorus, other nuclei
- requires specialized hardware
- RF amps, coils, receivers
New Orleans 2001
5MRS techniques
- Single voxel
- PROBE
- 2D multi-voxel
- PROBE SI
- chemical shift imaging/ MRSI
- 3D CSI
- 3D focal CSI
6PROBEsingle voxel proton MRS
X
PhD
- fully automated prescan, scan
- shimming
- water suppression
- 4 5 minute complete acquisition
- Short (PRESS, STEAM) and long TE (PRESS)
7single voxel MRS localization
8MRS acquisition modes
- STEAM
- stimulated echo acquisition mode
- short TE single voxel acquisition
- PRESS
- point resolved spectroscopy
- Twice the SNR of STEAM
- Short and long TE single voxel techniques now
possible - Long TE MRSI
9Proton MRS
10Lactate
Cho
NAA
Cr
Lipid
Cr
MI
11(No Transcript)
12Short TE PRESS
- 1500 / 35
- probe-p, scan mode 1
- 96 nex scans
- 256 x 128
- FOV 21, fAP
- 20 mm thick
- 8 nex, 254
13NAAN-acetyl aspartate
- putative neuronal marker
- decreased concentration seen in focal and
regional brain lesions - infarction, ischemia, hypoxia, hemorrhage
- neoplasm, multiple sclerosis,
- abscess, herpes encephalitis
- epilepsy, DAT, NPH, TBI
- Canavans disease elevated NAA
14NAA
15Choline (Cho)
- marker of membrane synthesis
- high concentration seen in
- neoplasm
- developing brain
- low concentration seen in
- stroke
- liver disease
- dementia
16Creatine (Cr)
- supplier of phosphate to convert ADP to ATP
- gray matter concentration 20 gt WM
- high concentration
- increases with age
- head trauma
- hyperosmolar states
- low concentration
- neoplasm, stroke, hypoxia
- infant brain
17Lactate (Lac)
- end product of anaerobic glycolysis
- nonspecific accumulation in
- hypoxia, anoxia, infarction, hemorrhage
- neoplasm
- infection
- demyelinating disease
- hydrocephalus
- inborn errors of metabolism
Kuala Lumpur 2000
lactate
18Lactate
TE 35
TE 144
19(No Transcript)
20Glxglutamate, glutamine
- glutamate is an excitatory neurotransmitter
- glutamine is a product of the reaction of
glutamate with NH3 - elevated concentration
- hepatic encephalopathy
- hypoxia
- low concentration
- ? Alzheimers disease
21Ross B, Michaelis T Clinical Applications of MRS.
Magnetic Resonance Quarterly, Vol 10, No 4, 1994
22Myoinositol (mI)
- ? astrocyte marker, myelin breakdown product
- high concentration
- DAT
- developing brain
- multiple sclerosis
- HIV infection
- low concentration
- infarction, neoplasm
- hepatic encephalopathy
23DAT
24single voxel MRSclinical utility
- focal lesion characterization
- characteristic lesion signature
- Ddx tumor from abscess, infarction, etc.
- global / regional lesions
- hepatic encephalopathy
- dementia, epilepsy
Las Vegas 2000
NYC 2001
25(No Transcript)
26(No Transcript)
27(No Transcript)
28Cerebral neoplasmMRS findings
Cho
- NAA decreased
- most lack neurons
- lactate accumulation
- high activity regions, cysts, necrosis
- lipid increased
- necrosis, metastatic adenoCA
- choline elevated
- accelerated membrane synthesis
New Orleans 2001
29(No Transcript)
30Short TE
long TE
New Orleans 2002
3135 yo female seizures
32New Orleans 2000
33(No Transcript)
34(No Transcript)
35Taipei 2002
Vail 2004
36(No Transcript)
37Cerebral neoplasmrole of MRS / MRSI
- characterization
- mass lesion DDx
- extent
- tumor infiltration vs. edema
- primary vs. metastasis
- surveillance
- post op enhancement vs. residual tumor
- recurrent tumor vs. radiation necrosis
- non-enhancing lesions
Snowmass 2004
38Vail 2003
Snowmass 2004
39(No Transcript)
40(No Transcript)
41(No Transcript)
42Vail 2003
43(No Transcript)
44H. Mahendran, M.D., Delhi
45H. Mahendran, M.D., Delhi
46Clinical MRSlesion characterization
- neoplasm
- infarction
- infection
- multiple sclerosis
- lesions in HIV patients
- tumor vs. radiation necrosis
Mardi Gras NO 2001
47post partum seizures
Vail 2003
48Palos Verdes 2000
49New Orleans 2000
50AIDS r/o infection
Stockholm 2002
51New Orleans 2002
52pre-op brain tumor
Glasgow 2001
R. Tien, M.D. Duke Univ
53Glasgow 2001
54(No Transcript)
55(No Transcript)
56Snowmass 2004
57(No Transcript)
5830 yo male with tumor
59(No Transcript)
60Indian patient with seizures
Istanbul 2000
61(No Transcript)
62(No Transcript)
63Jerusalem 2000
64Cerebral abscessMRS findings
- NAA, Cho, Cr decreased
- may see resonances from microorganism and
proteolysis end-products - lactate
- succinate (2.4 ppm), acetate (1.9)
- alanine (1.5), amino acids (0.9)
65Lac
abscess
Suc
AA
Acetate
Ala
66(No Transcript)
67(No Transcript)
68(No Transcript)
69Nantucket 2000
70Chang L In Vivo MRS in HIV and HIV-related
Brain Diseases
71Chang L In Vivo MRS in HIV and HIV-related
Brain Diseases
72AIDS
Nantucket 2000
73New Orleans 2000
74Chang L In Vivo MRS in HIV and HIV-related
Brain Diseases
753T MRSI
76AIDS
77Chang L In Vivo MRS in HIV and HIV-related
Brain Diseases
78Chang L, Miller B, McBride D, et. al. Proton MR
Spectroscopy of Brain Lesions in AIDS
79Multi-voxel spectroscopyMRSI
- multiple spectra in single acquisition
- matrix of spectra
- gray (color) scale metabolite display
- integrate with structural data
- overlay on structural images with variable
opacity - simultaneous evaluation of large areas of brain
- contralateral comparison information
Hermosa Beach 2000
80Long TE PRESS 2D CSI
- 1000 / 144 PRESS
- 256 x 128, FOV 21, fAP
- 10 mm thick, 1 nex
- fast
- 12 x 12, 144 voxels, 228
- 16 x 16, 256 voxels, 420
- 24 x 24, 576 voxels, 940
- preset or optimized water suppression
81(No Transcript)
82NAA
Choline
Chronic MS plaque
83(No Transcript)
84Cho
85Meningioma
NAA
Cho
86lesion characterization
brainstem glioma
NAA
Cho/NAA
Choline
87extent
88FLAIR
NAA
Cho/NAA
89FLIR T1
NAA
Cho/NAA
90Choline
NAA
Lactate - lipid
91Cho / NAA
Pelican Hill
92(No Transcript)
93Multi-voxel MRSI
256 voxels 5 minutes
94Multi-voxel MRSI
256 voxels 5 minutes
Cho / NAA
95Multi-voxel MRSI
edema
96Cho/NAA
97Cho / NAA
NAA
Choline
98(No Transcript)
99Multi-voxel MRSI TE 144
256 voxels 5 minutes
100(No Transcript)
101(No Transcript)
1023T MRSI
tumor vs. radiation necrosis
1033D CSI
1043D focal CSI
- 1000 / 144 (288) PRESS
- 50 (3-100) mm voxel thickness
- 8 (8-16) locs (slices) per slab (volume)
- 8 mm spacing (thickness)
- 8 x 8, 512 voxels (64 / slice), 832
- very selective spatial saturation
- 6 defaults at edge VOI
- 4 explicitly prescribed
- 256 x 128, FOV CSI volume, fAP, 1 nex
105(No Transcript)
106(No Transcript)
107(No Transcript)
108(No Transcript)
109(No Transcript)
110glioma
111(No Transcript)
112Cho
Lac Lipid
Cho / NAA
NAA
1138 channel NV coil
1143D CSI 3T
115(No Transcript)
116(No Transcript)
117(No Transcript)
118TwinSpeed 3D focal CSI
119(No Transcript)
120(No Transcript)
121(No Transcript)
122(No Transcript)
123(No Transcript)
124acetate
NAA
Lac
125Multi-voxel MRSI
- thorough lesion characterization
- lesion mapping
- nature, extent
- multiple biopsies
- edema, wall, center
- reduce sampling error
- complex lesions
- radiation necrosis / post operative change vs.
tumor
126Multi-voxel MRSI
- regional lesions
- epilepsy
- dementia
- traumatic brain injury
Steamboat 2001
127(No Transcript)
128NAA
Choline
mesial temporal sclerosis
129MTS
130L
MTS
R
L
R
131PSIR
NAA
Cho
132Traumatic brain injury
133Clinical MRScost / clinical benefits
- refine lesion characterization
- facilitate early diagnosis, treatment
- decrease invasive diagnostic and therapeutic
procedures - reduce need for follow-up, ancillary studies
- impact workup / Rx of global brain lesions
- facilitate diagnosis DAT, TBI
- lateralize TLE
NYC 2001
134Prostate MRSI
Citrate
Cho
Cho
CA
normal
135(No Transcript)
136(No Transcript)
1373D PROBE SI
Citrate
ChoCr
Cho
Cr
138Metabolic Identification Of Prostate Cancer
Cancer
Healthy
Axial T2 Weighted MRI
0.24 cc in vivo proton spectrum from a 3D array
of spectra
University of California San Francisco
139Prostate MRSIimpact
- traditional role for imaging is staging
- poor clinical acceptance
- insufficient accuracy?
- reduced surgery?
- MRSI improves specificity
- differentiate benign SI changes from malignancy
- allows identification and localization of cancer
140Prostate MRSIclinical role
- high PSA, negative biopsy
- options
- repeat biopsy blindly
- repeat biopsy blindly
- repeat biopsy blindly
- identify and localize cancer with MRSI
- perform directed biopsy for characterization
141Prostate MRSIclinical role
- positive biopsy
- guide super selective radiation therapy to
cancerous portion of prostate gland
142Outcome studies
- HIV
- About 20 of MRI- patients have significant MRS
changes (Marseilles, France) - Adrenoleukodystrophy
- 25 of MRI- boys with affected sib have
significant MRS abnormalities (Gottingen,
Germany) - Near drowning
- MRS defined 5/5 good and 11/12 poor outcome
between days 2 and 4 after rescue (Pasadena,
California) - Temporal lobe epilepsy
- 55/60 patients successfully lateralized (London,
UK)
143Moats, Watson, Shonk, et al. SMRM 1993.
144Case study
new onset seizures
145(No Transcript)
146Case study Diagnosis Infarction
147Final exam
New Orleans 2000
148Dyslexia
149Schizophrenia
150Depression
151(No Transcript)
152Mardi Gras NO 2001
153Clinical MRSI
- Lawrence N. Tanenbaum, M.D. FACR
- New Jersey Neuroscience Institute
- Seton Hall School of Graduate Medical Education
- JFK Medical Center Edison Imaging
- Edison, New Jersey